TY - JOUR
T1 - Epidemiology of Heart Failure with Preserved Ejection Fraction
AU - Dhingra, Abhinav
AU - Garg, Aayushi
AU - Kaur, Simrat
AU - Chopra, Saurav
AU - Batra, Jaspreet Singh
AU - Pandey, Ambarish
AU - Chaanine, Antoine H.
AU - Agarwal, Sunil K.
N1 - Publisher Copyright:
© 2014, Springer Science+Business Media New York.
PY - 2014/12
Y1 - 2014/12
N2 - The prevalence of heart failure (HF) and its subtype, HF with preserved ejection fraction (HFpEF), is on the rise due to aging of the population. HFpEF is convergence of several pathophysiological processes, which are not yet clearly identified. HFpEF is usually seen in association with systemic diseases, such as diabetes, hypertension, atrial fibrillation, sleep apnea, renal and pulmonary disease. The proportion of HF patients with HFpEF varies by patient demographics, study settings (cohort vs. clinical trial, outpatient clinics vs. hospitalised patients) and cut points used to define preserved function. There is an expanding body of literature about prevalence and prognostic significance of both cardiovascular and non-cardiovascular comorbidities in HFpEF patients. Current therapeutic approaches are targeted towards alleviating the symptoms, treating the associated comorbid conditions, and reducing recurrent hospital admissions. There is lack of evidence-based therapies that show a reduction in the mortality amongst HFpEF patients; however, an improvement in exercise tolerance and quality of life is seen with few interventions. In this review, we highlight the epidemiology and current treatment options for HFpEF.
AB - The prevalence of heart failure (HF) and its subtype, HF with preserved ejection fraction (HFpEF), is on the rise due to aging of the population. HFpEF is convergence of several pathophysiological processes, which are not yet clearly identified. HFpEF is usually seen in association with systemic diseases, such as diabetes, hypertension, atrial fibrillation, sleep apnea, renal and pulmonary disease. The proportion of HF patients with HFpEF varies by patient demographics, study settings (cohort vs. clinical trial, outpatient clinics vs. hospitalised patients) and cut points used to define preserved function. There is an expanding body of literature about prevalence and prognostic significance of both cardiovascular and non-cardiovascular comorbidities in HFpEF patients. Current therapeutic approaches are targeted towards alleviating the symptoms, treating the associated comorbid conditions, and reducing recurrent hospital admissions. There is lack of evidence-based therapies that show a reduction in the mortality amongst HFpEF patients; however, an improvement in exercise tolerance and quality of life is seen with few interventions. In this review, we highlight the epidemiology and current treatment options for HFpEF.
KW - Diastolic heart failure
KW - Epidemiology
KW - Preserved ejection fraction
KW - Prevalence
UR - http://www.scopus.com/inward/record.url?scp=84920834648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84920834648&partnerID=8YFLogxK
U2 - 10.1007/s11897-014-0223-7
DO - 10.1007/s11897-014-0223-7
M3 - Review article
C2 - 25224319
AN - SCOPUS:84920834648
SN - 1546-9530
VL - 11
SP - 354
EP - 365
JO - Current heart failure reports
JF - Current heart failure reports
IS - 4
ER -